Bryan, Garnier & Co expands its Equity Capital Markets capabilities with the hiring of Pierre Kiecolt-Wahl as Managing Director - ECM

Paris / New-York, May 9th, 2016 - Bryan, Garnier & Co, the leading pan-European Investment Bank focusing on growth companies, is pleased to announce that Pierre Kiecolt-Wahl has joined the firm as Managing Director, ECM, where he will lead Bryan, Garnier & Co’s equity capital markets efforts throughout Europe.

“Over the past 15 years, Pierre has gained significant experience in advising innovative growth companies and investors in our core sectors of expertise, dealing with a wide variety of situations in more than twenty different markets across Europe, Asia and the US,” said Greg Revenu, Managing Partner and co-founder of the group. “He adds critical insight and equity capital market expertise to our firm, so we can further deliver for our clients. We are delighted he has decided to join the team.”

An American/French citizen, Pierre brings more than 15 years of international equity capital markets knowledge with organizations such as Bank of America, Lehman Brothers, Jefferies and Citi, based in San Francisco, London and Hong Kong.

He has participated in more than 30 transactions across Europe and Asia including a significant number in the biotech and pharma sectors, including IPOs and follow-ons for Algeta, Almirall, Alapis, Bavarian Nordic, Cosmo Pharma, Medivir, Molmed, Thrombogenics,  and Zealand Pharma (with Bryan Garnier), as well as in TMT and consumer including offerings for Tele Atlas, Cineworld, and Ocado, amongst others.

“Bryan Garnier has one of the leading ECM franchises and in particular, has a unique track record of successfully raising capital for innovative European growth companies across both the European and US markets. The strength of its pan-European growth focused equity research and the firm's ability to access leading investors in both Europe and the US makes Bryan Garnier a highly differentiated investment bank in Europe. Combined with the firm’s focus on the most successful European growth companies and delivering for its clients, the Bryan Garnier platform is extremely compelling and I am very pleased to be joining.  I look forward to leveraging my experience and relationships in support of the continued success of our clients and the firm,” Mr. Kiecolt-Wahl said.

About Bryan, Garnier & Co (www.bryangarnier.com)

Bryan, Garnier & Co is an independent investment bank specialized in European growth companies, providing them with Equity Research & Brokerage, Asset Management and Corporate Finance services. With more than 150 professionals throughout London, Paris, Munich, New York, Geneva and New Delhi, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique. Bryan, Garnier & Co is a leading advisor to European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital markets, LBOs and private placements. Bryan, Garnier & Co is authorized and regulated by the Financial Conduct Authority (FCA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European capital markets.

In 2015, Bryan, Garnier & Co completed more than 35 transactions on European growth companies, including landmark transactions such as the acquisition of Metrologic from Carlyle, the sale of Codenomicon to Synopsis, the sale of cybersecurity Lexsi to Orange, the €25m private placement for Jahia, the IPOs of Bone Therapeutics or Amoeba on Euronext or Celyad and Galapagos on the Nasdaq.

In 2014 and 2015, Bryan, Garnier & Co was the most active investment bank involved in the IPO of European growth companies on the US Nasdaq. In December 2015, Bryan Garnier completed the acquisition of Cartagena Capital in Germany.